CGBIO

What CGBIO does

CGBIO is a South Korea-based regenerative medicine and medical device company founded in 2008, operating as an affiliate of Daewoong Group. The company develops and manufactures a diversified portfolio spanning aesthetic medicine (hyaluronic acid filler brands GISELLELIGNE and Eloyan, plus facial implant FACETEM), orthopedic and spine surgery (NOVOSIS growth-factor bone graft substitute, ExCender expandable cage, Colonnade minimally invasive screw system), patient-specific implants (EASYMADE TI — FDA 510(k) cleared for cranial and craniofacial reconstruction, manufactured via Laser Powder Bed Fusion 3D printing and deliverable to US hospitals within five days of CT intake), and wound care products (Curasys ME, CGDerm One-Step, CG GEL). CGBio Medtech, a KOSDAQ-listed subsidiary approximately 40.4% owned by CGBIO, is transitioning from orthopedic implants into dental implants and ECM skin boosters, supported by AATB-certified human tissue procurement capabilities and a new Uijeongbu plant tripling capacity to 600,000 units annually in Q1 2026.

CGBIO generates revenue through hardware sales across medical device categories, with the primary commercial engine being channel partnerships rather than direct sales. In May 2026, the company entered an exclusive distribution agreement with DePuy Synthes (Johnson & Johnson) covering NOVOSIS in the United States, Canada, and Australia, building on a prior February 2025 arrangement across Korea, Taiwan, Thailand, India, Hong Kong, and Macau. In June 2026, CGBIO signed a five-year strategic partnership with Zhejiang Ups Biotechnology (UPS BIO) to launch Eloyan HA filler in China targeting approximately 30 billion won (~$20 million) in cumulative brand sales. Regional supply agreements with Neuva Era (Singapore, Malaysia), MediNova Healthcare (Pakistan), HCT Regenerative (Taiwan), and Variance Trading (Philippines) extend reach into additional Asian markets. Export revenue reached $21.8 million in 2025, up 31% YoY.

The company is undergoing a significant ownership transition: as of March 2026, Daewoong Group is negotiating the sale of a 51% stake to IMM Private Equity at a potential valuation of up to 1 trillion won ($680 million). CGBIO pursues a dual go-to-market strategy combining global distribution anchors for developed markets with regional exclusive distributors for Asian and emerging markets, complemented by medical education forums (Bangkok 2026 spine surgery forum with 50+ surgeons from 8 Asian countries) and trade show participation (KIMES 2026 yielding KRW 5.3 billion in contract signings).

Name

CGBIO

Legal name

CGBIO

Website

https://cgbio.co.kr

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

CGBIO is a South Korea-based regenerative medicine company developing and distributing bone graft substitutes, patient-specific 3D-printed titanium implants, HA dermal fillers, and wound care products. It serves spine surgeons, aesthetic clinics, and craniofacial specialists globally via partnerships with DePuy Synthes and regional distributors.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Regenerative medicine devices
• Bone graft substitutes
• Spinal implant systems
• Patient-specific implants
• Aesthetic medical devices

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of medical devices including aesthetic products (fillers, FACETEM, CG GEL, CGDerm One-Step), wound care products, bone graft substitutes (NOVOSIS), and patient-specific implants (EASYMADE TI) through distribution partnerships.
2. Distribution Agreement Revenue: Revenue generated through exclusive distribution agreements with major partners like DePuy Synthes covering orthopaedic portfolio including spine, craniomaxillofacial, and trauma applications in US, Canada, Australia, and other markets.
3. Multi-Brand HA Filler Sales: Sales of hyaluronic acid filler brands including GISELLELIGNE and newly launched Eloyan through China partnership with UPS BIO, targeting cumulative brand sales of approximately 30 billion won.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

CGBIO manufactures and distributes a diversified portfolio of regenerative medicine and medical device products spanning aesthetic medicine (hyaluronic acid fillers, skin boosters, facial implants), orthopedic and spine surgery (growth-factor bone graft substitutes, expandable cages, minimally invasive screw systems), cranial and craniofacial reconstruction (patient-specific 3D-printed titanium implants), wound care, and dental implants. The company sells through major distribution partnerships (DePuy Synthes for developed Western markets, UPS BIO for China) and regional Asian distributors.

Product overview

CGBIO is a regenerative medicine and biotechnology company offering a diversified medical device portfolio across four main categories: aesthetic (hyaluronic acid fillers including Eloyan, GISELLELIGNE, FACETEM, and ECM skin boosters), wound care (Curasys ME and wound care products), bone and spine (NOVOSIS growth-factor bone graft substitute, EASYMADE TI patient-specific titanium implants, ExCender expandable cage, Colonnade screw system), and surgical products (CG GEL). The company operates through its subsidiary CGBio Medtech (40.4% owned) which focuses on dental implants and ECM skin boosters. CGBIO partners with DePuy Synthes (Johnson & Johnson) for global distribution of NOVOSIS and is expanding into the Chinese market through UPS BIO partnership.

Differentiator

Problem solved

Functional benefit

Brands

• GISELLELIGNE: Hyaluronic acid filler brand for the Chinese market.
• Eloyan
• NOVOSIS
• EASYMADE TI
• FACETEM
• Curasys ME
• CG GEL
• CGDerm One-Step
• ExCender
• Colonnade

Products and services

• EASYMADE TI Patient-specific titanium implant for cranial and craniofacial reconstruction, manufactured using Laser Powder Bed Fusion 3D printing with medical-grade titanium alloy, deliverable to U.S. hospitals within five days of receiving patient CT images. First Korean company with FDA 510(k) clearance for this category.
• NOVOSIS Advanced growth-factor bone graft substitute used in orthopedic and spine procedures. Distributed by DePuy Synthes in the U.S., Canada, Australia, and other markets; currently under FDA investigational device exemption (IDE) study for spine applications.
• FACETEM Facial aesthetic implant product. Distributed exclusively by Neuva Era in Singapore and Malaysia, and by MediNova Healthcare in Pakistan.
• Curasys ME Wound care product showcased at KIMES 2026 as part of CGBIO's comprehensive medical device portfolio.
• CG GEL Medical device product featured in CGBIO's portfolio spanning aesthetic and surgical fields.
• CGDerm One-Step Regenerative dermatology product distributed by HCT Regenerative Co., Ltd. in Taiwan.
• ExCender Expandable cage used in minimally invasive spine surgery procedures. Featured at the International Minimally Invasive Spine Surgery Education Forum in Thailand.
• Colonnade Minimally invasive screw system used in spine surgery, featured alongside NOVOSIS and ExCender at cadaver training stations during the spine surgery education forum.
• Eloyan Hyaluronic acid filler brand launched in China through five-year strategic partnership with Zhejiang Ups Biotechnology (UPS BIO), combining CGBIO's NMPA-approved HA filler products with UPS BIO's aesthetic clinic distribution network.
• GISELLELIGNE Hyaluronic acid filler brand with existing presence in the Chinese market prior to the Eloyan launch.
• ECM Skin Boosters Skin booster products developed by CGBio Medtech leveraging AATB-certified human tissue procurement capabilities, part of its expansion from orthopedic implants into comprehensive implant solutions.
• Dental Implants Dental implant products developed by CGBio Medtech as part of its transition into a comprehensive implant company, supported by a new Uijeongbu plant tripling production capacity to 600,000 units annually.

Quantifiable outcome

• 31% annual export growth with $21.8 million in exports (2025)
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Zhejiang Ups Biotechnology (UPS BIO)coreChannel Partner/ Reseller/ Distributor · 2 June 2026Five-year strategic partnership to launch new hyaluronic acid filler brand called Eloyan in China. Partnership combines CGBIO's NMPA-approved HA filler products with UPS BIO's extensive distribution network of aesthetic clinics and KOL-driven marketing capabilities. Two companies targeting cumulative brand sales of approximately 30 billion won (~$20 million) through multi-brand strategy building on existing GISELLELIGNE brand presence.
• DePuy Synthes (Johnson & Johnson)coreChannel Partner/ Reseller/ Distributor · 26 May 2026DePuy Synthes entered exclusive distribution agreement with CGBIO for NOVOSIS growth-factor bone graft substitute covering United States, Canada, and Australia across orthopaedic portfolio including spine, craniomaxillofacial, and trauma. IDE study for spine procedures approved and actively enrolling in U.S. Agreement builds on prior February 2025 arrangement covering Korea, Taiwan, Thailand, India, Hong Kong, and Macau. DePuy Synthes gains rights of first negotiation for additional global markets.
• Neuva EracoreChannel Partner/ Reseller/ Distributor · 7 April 2026Exclusive supply agreement for FACETEM in Singapore and Malaysia signed at KIMES 2026, part of KRW 5.3 billion total contract value.
• MediNova HealthcarecoreChannel Partner/ Reseller/ Distributor · 7 April 2026Exclusive distribution agreement for FACETEM in Pakistan signed at KIMES 2026.
• HCT Regenerative Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 7 April 2026Supply agreement for CGDerm One-Step in Taiwan signed at KIMES 2026.
• Variance Trading CorporationcoreChannel Partner/ Reseller/ Distributor · 7 April 2026Supply agreement for wound care products in the Philippines signed at KIMES 2026.
• Siriraj Hospital, Chulalongkorn University, The Catholic University of KoreaminorStrategic or Co-development Partner · 30 March 2026Co-organized International Minimally Invasive Spine Surgery Education Forum at Siriraj Hospital in Bangkok, Thailand with over 50 spine surgeons from 8 Asian countries. CGBIO led two of six cadaver training stations using NOVOSIS, ExCender, and Colonnade products, positioning Thailand as hub for minimally invasive spine surgery in Asia.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Integra LifeSciences: US-listed regenerative medicine and surgical implant company offering bone graft substitutes, dural repair, wound care, and patient-specific cranial implants (e.g., Craniomaxillofacial solutions). Most directly comparable to CGBIO across the orthobiologics, CMF, and wound care pillars.
• Organogenesis: US-listed regenerative medicine company focused on advanced wound care and skin substitutes (Apligraf, Dermagraft) using allograft and tissue-engineering platforms. Highly comparable to CGBIO's ECM skin booster and wound care product strategy.
• MiMedx: US-listed regenerative medicine company using placental tissue allografts for wound care and surgical applications. Comparable to CGBIO's tissue-based regenerative offerings (ECM skin boosters, allograft bone grafts) and shares AATB-adjacent tissue procurement orientation.
• LG Chem (Life Sciences): Korean conglomerate life sciences division with a major hyaluronic acid dermal filler and orthobiologics franchise. Most direct Korean peer to CGBIO's Eloyan/GISELLELIGNE filler business and competes in the same home-market aesthetics channel.
• Humedix: Korean specialty aesthetics and orthobiologics company (subsidiary of Huons) with cross-linked HA dermal fillers (e.g., Elravie) and regenerative products. Direct Korean competitor to CGBIO's HA filler portfolio and aesthetics franchise.

Broad incumbents

• Stryker: Global orthopaedic and spine medtech incumbent with extensive bone graft substitute and spinal implant portfolios. Comparable to CGBIO's NOVOSIS, ExCender, and Colonnade product lines but at vastly larger scale and broader portfolio.
• Medtronic: Largest spinal implant and orthobiologics player globally with Infuse bone graft and a comprehensive spine portfolio. Directly comparable to CGBIO's spine-focused offerings, with much greater commercial scale and US sales infrastructure.
• Johnson & Johnson (DePuy Synthes): CGBIO's exclusive distribution partner for NOVOSIS in US/Canada/Australia and a global orthopaedic incumbent. Closely comparable as the channel through which CGBIO's bone graft substitute reaches surgeons, and as the dominant orthobiologics competitor.
• Galderma: Global dermatology and aesthetics pure-play with the leading portfolio of hyaluronic acid fillers (Restylane, Emervel). Comparable to CGBIO's HA filler business as the dominant global competitor in the China and Asia-Pacific aesthetics market.

Emerging players

• GC Cell (formerly GC Pharma): Korean cell therapy and regenerative medicine company with emerging wound care and tissue engineering products. Comparable as a Korean-listed regenerative medicine peer addressing similar clinical end-markets (wound healing, tissue regeneration) and competing for the same KOL networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/cgbio.official
• LinkedInlinkedin.com/company/cgbiokr

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CGBIO